Talc has been in American bathrooms for more than a century. It is soft, it absorbs moisture, it stops chafing, and for generations it was the first thing a parent reached for after a bath and the last thing a woman used before getting dressed. Nobody thought of it as a chemical exposure. It was a habit, and habits do not get written down.
That habit is now the basis of the largest multidistrict litigation pending in the federal court system, and the reason a Nevada woman diagnosed with ovarian cancer, or a family whose mother died of mesothelioma without ever working around insulation, may have a claim they have never considered.
This subject attracts a great deal of loose talk, some of it from law firms. What follows sticks to what can be checked. That means what the FDA has actually said and done, what remains genuinely open scientifically, where the litigation stands procedurally, and how Nevada’s deadlines apply to a disease that can take decades to appear.
What Talc Is and Where the Asbestos Question Comes From
Talc is a naturally occurring mineral mined from the earth, a hydrous magnesium silicate made up of magnesium, silicon, oxygen and hydrogen. In cosmetics it absorbs moisture, prevents caking, makes facial makeup opaque and improves how a product feels on skin. It appears in far more products than baby powder. Body powder, blush, eye shadow, foundation, pressed powder and children’s makeup kits have all contained it.
Asbestos is also a naturally occurring silicate mineral, but with a different crystal structure, and unlike talc it is a known carcinogen when inhaled. The two minerals can form in close proximity in the earth. That geological fact is the origin of the entire contamination issue. As the FDA describes it, there is the potential for contamination of talc with asbestos, which is why it matters that mining sites are selected carefully and that the ore is tested sufficiently.
None of this is a recent discovery. The FDA notes that questions about potential contamination of talc with asbestos have been raised since the 1970s. Separately, published scientific literature going back to the 1960s has suggested a possible association between the use of powders containing talc in the genital area and the incidence of ovarian cancer. Two distinct concerns, running in parallel, for roughly half a century.
What the FDA Has Actually Said and Done
Start with the regulatory posture, because it explains a great deal about how these products reached the shelf.
Under the Federal Food, Drug and Cosmetic Act, cosmetic products and ingredients, with the exception of color additives, do not have to undergo FDA review or approval before they go on the market. Cosmetics must be properly labeled and must be safe for use by consumers under labeled or customary conditions of use, and the agency monitors for safety problems and acts when needed to protect public health. Before the FDA can take action against a cosmetic product, it needs sound scientific data showing that the product is harmful under its intended use. There was no pre market gatekeeper standing between talc powder and the consumer.
On the ovarian cancer question, the agency’s own language is careful and deserves quoting rather than paraphrasing. The FDA states that the literature since the 1960s has suggested a possible association, but that these studies have not conclusively demonstrated such a link, or if such a link existed, what risk factors might be involved, and that more research is needed to confirm whether there is a link or not. Any firm telling you the science is settled is not describing what the regulator says. The FDA page on talc in cosmetics is public and lays all of this out.
On contamination the agency has been considerably more active. In October 2019 the FDA issued a safety alert advising consumers to stop using certain cosmetic products that had tested positive for asbestos, and that same month a baby powder manufacturer voluntarily recalled product for asbestos. The agency has run repeated sampling programs since, testing talc containing cosmetic products for asbestos using polarized light microscopy and transmission electron microscopy, with results released from a year long assignment reported in 2020 and from further surveys covering 2021, 2022 and 2023.
Rulemaking has moved less cleanly. In December 2024 the FDA proposed a rule to establish and require standardized testing methods for detecting and identifying asbestos in talc containing cosmetic products, acting under section 3505 of the Modernization of Cosmetics Regulation Act of 2022. On November 28, 2025 the agency announced that it was withdrawing that proposed rule, stating it was responding to comments received during the comment period that warrant further consideration and assessment before final regulations are issued. As of the agency’s most recent update to its talc page in January 2026, there is still no finalized federal standardized testing method for asbestos in talc containing cosmetics.
The Two Different Claims, and Why the Difference Matters
People say “the talc lawsuits” as though there is one claim. There are two, they rest on different biology, and they are proven in different ways.
The ovarian cancer claim is by far the larger of the two by volume. It generally involves long term perineal application of talc powder, and it turns on the epidemiological literature the FDA describes as suggestive but not conclusive, combined with evidence about what manufacturers knew regarding contamination and what they told consumers.
The mesothelioma claim is a different animal. Mesothelioma is a cancer of the lining of the lungs, abdomen or heart that is strongly associated with asbestos exposure. A mesothelioma claim built on talc rests on the contamination pathway, meaning the allegation that the powder itself carried asbestos fibers that were inhaled during ordinary use. These cases frequently involve people with no occupational asbestos history at all, which is exactly what puts the cosmetic product at the center of the inquiry.
The distinction has practical consequences. A mesothelioma diagnosis in someone who never worked around insulation, shipyards, brake linings or construction materials should prompt a specific question about household and cosmetic sources, and it is a question a treating oncologist may never think to ask. If nobody asks it, the exposure history is never taken, and the file that would support a claim is never built.
Where the Talc Litigation Stands Right Now
Federal talc cases against Johnson and Johnson are consolidated in a multidistrict litigation. The Judicial Panel on Multidistrict Litigation transferred In re Johnson and Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation, MDL 2738, to the District of New Jersey in October 2016, where it is assigned to Judge Michael A. Shipp under master docket number 3:16-md-2738. The Panel’s statistics report dated July 1, 2026 lists 68,435 actions pending in that proceeding, which is the largest number of pending actions in any MDL in the federal system.
You may also have read about efforts to move talc liability into bankruptcy. That history has been contested and has changed direction more than once. We are not going to characterize its current status in an article that may be read many months after it was written, and you should be skeptical of any law firm page that does so without a date attached. Ask about the current posture in a conversation, where the answer can be given as of a specific day.
What can be stated plainly is what an MDL is and is not. It consolidates federal cases before a single judge for coordinated pretrial handling and rulings on common issues. It is not a class action. It does not merge individual claims into one claim. It does not decide whether any particular person recovers, and being part of one is not an assurance of anything. We do not predict outcomes, timelines or values in these cases, and nobody honestly can. The same caution belongs on toxic hair relaxer claims and other consumer product cancer litigation, where advertising routinely outruns the proof.
Nevada’s Deadline and the Problem a Latent Disease Creates
Nevada allows two years to bring an action to recover damages for injuries to a person caused by the wrongful act or neglect of another, under NRS 11.190(4)(e). Two years is not a long time for a disease that may take decades to develop and months more to diagnose correctly.
Nevada applies a discovery based approach to accrual where the injury or its cause is not immediately apparent, so the period generally begins when the claimant knew, or through reasonable diligence should have known, of the facts giving rise to the claim, rather than on the date of the last use of the product. How that principle applies to a particular diagnosis is fact specific and is regularly contested. The date of diagnosis, the date a physician first connected the disease to a product, and what a reasonable person would have known from public reporting at the time all become live issues that the defense will litigate.
Where the person has died, Nevada’s wrongful death statute, NRS 41.085, identifies the heirs and the personal representative of the estate as the parties who may bring claims, and those claims carry their own timing. Families sometimes lose a year assuming that the estate must be fully probated before anything can be filed. It does not work that way, and the safe assumption is that a clock is already running. Our discussion of the statute of limitations in personal injury cases covers the general framework, and our page on Nevada wrongful death claims explains how a death case is structured.
Product Identification Decides More Talc Cases Than Science Does
Scientific causation gets the attention. Product identification quietly decides more cases than causation ever will.
To bring a claim, a person has to establish which product was used, over what period, and how often. That sounds straightforward until you try to reconstruct thirty years of a daily bathroom habit for someone who is now seriously ill or has already died. The evidence that carries this burden is ordinary and human.
- Statements from family members, roommates and partners who saw the container in the house year after year
- Photographs from birthdays, holidays and bathrooms where a container is visible in the background
- Purchase records, loyalty card histories and pharmacy account histories
- Any containers still in the house, a closet or a storage unit, which should be kept rather than thrown out
- Medical records noting powder use, and the complete pathology report including any tissue analysis
Preserve the physical product if it still exists anywhere. An unopened or partly used container from the relevant period is evidence in a way that no recollection can be, because it can be tested. The same evidentiary discipline that governs other injuries caused by defective products applies here, and it begins long before anything is filed.
Nevada’s modified comparative negligence rule under NRS 41.141 applies to these claims as it does to other injury claims, barring recovery where the claimant’s share of fault exceeds 50 percent and otherwise reducing damages in proportion to that share. In a consumer product case that argument usually arrives dressed as a claim about warnings and about how the product was actually used.
Talking to The Bourassa Law Group About a Talc Claim
If you or someone in your family used talc powder regularly and has been diagnosed with ovarian cancer or mesothelioma, a few things are worth doing before you speak with anyone.
- Write down the brands used, the years, roughly how often, and who can confirm it
- Request the complete medical file, including pathology and any surgical reports, rather than a discharge summary
- Keep any product containers and do not discard them
- Note the date you first heard that a product might be connected to the diagnosis, because that date can matter to the limitations analysis
The Bourassa Law Group offers a free consultation to review the product history, the medical documentation and the Nevada deadlines that apply to your situation. We will tell you what the records support and what they do not, and we will not put a number on a case at a first meeting, because a responsible answer to that question does not exist yet. Our page on dangerous drug and product claims explains how we approach this category of case generally.
This article is general information about Nevada law and about the public record maintained by federal agencies and the federal courts. It is not legal advice, and reading it does not create an attorney client relationship. Every claim depends on its own facts, product history and medical proof, so speak with a licensed Nevada attorney about your circumstances, or read more about Nevada personal injury representation.
1-800-870-8910